Literature DB >> 15357645

Interferon-gamma-associated responses to woodchuck hepatitis virus infection in neonatal woodchucks and virus-infected hepatocytes.

Y Wang1, J R Jacob, S Menne, C A Bellezza, B C Tennant, J L Gerin, P J Cote.   

Abstract

Acute hepatitis and recovery from woodchuck hepatitis virus (WHV) infection involves increased intrahepatic expression of interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) mRNAs. In the present study, recovery correlated with increased intrahepatic expression of mRNAs for major histocompatibility complex class 1 (MHC1), beta(2)-microglobulin, 2'5'-oligoadenylate synthetase (2'5'-OAS), and indoleamine dioxygenase (IDO). By comparison, acute WHV infection progressing to chronicity was associated with diminished expression of these IFN-gamma-associated mRNAs in liver. Transfection of WHV-infected primary hepatocytes (WPH) from WHV carriers with an IFN-gamma-expressing plasmid (pIFN-gamma) resulted in dose-dependent accumulations of MHC1, TNF-alpha, 2'5'-OAS, and IDO mRNAs within 96 h. Markers of T cells and immune-mediated cytotoxicity that accumulate in recovering liver were not apparent in WPH based on the relative lack of CD3, CD4, Fas ligand, perforin, and granzyme B mRNAs. Expression of pIFN-gamma, and TNF-alpha-expressing plasmid (pTNF-alpha), did not affect total WHV RNA, or fully double-stranded WHV DNA in WPH, but each reduced some of the replicative intermediate (RI) species of WHV DNA synthesis. WPH treated with recombinant IFN-alpha protein had a higher fold induction of 2'5'-OAS mRNA associated with partial reductions in WHV RNAs and the major RI species. Thus, IFN-gamma expression in carrier WPH induced several host responses often observed in liver of recovering woodchucks, and impaired a stage of WHV DNA synthesis by a non-cytolytic mechanism mediated by TNF-alpha. Local enhancement of IFN-gamma-associated responses in chronic WHV-infected hepatocytes may promote therapeutic antiviral effects, but additional effector mechanisms evident during recovery appear necessary for more complete clearance of WHV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357645     DOI: 10.1111/j.1365-2893.2004.00529.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B.

Authors:  Simon P Fletcher; Daniel J Chin; Donavan T Cheng; Palanikumar Ravindran; Hans Bitter; Lore Gruenbaum; Paul J Cote; Han Ma; Klaus Klumpp; Stephan Menne
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

3.  Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells.

Authors:  Richeng Mao; Jiming Zhang; Dong Jiang; Dawei Cai; Jessica M Levy; Andrea Cuconati; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

4.  Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.

Authors:  Mohammad-Khalid Parvez; Deepak Sehgal; Shiv-Kumar Sarin; Seemi-Farhat Basir; Shahid Jameel
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

5.  Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Simon P Fletcher; Daniel J Chin; Lore Gruenbaum; Hans Bitter; Erik Rasmussen; Palanikumar Ravindran; David C Swinney; Fabian Birzele; Roland Schmucki; Stefan H Lorenz; Erhard Kopetzki; Jade Carter; Miriam Triyatni; Linta M Thampi; Junming Yang; Dalal AlDeghaither; Marta G Murreddu; Marta G Murredu; Paul Cote; Stephan Menne
Journal:  PLoS Pathog       Date:  2015-09-09       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.